The pricing applies to an underwritten public offering of 10,526,000 shares of its common stock at a price of $1.90 per share. The gross proceeds of the company’s offerings are expected to be approximately $20 million before underwriting discounts, commissions and estimated offering expenses.
EyePoint Pharmaceuticals gave underwriters a 30-day purchase option for up to an additional 1,578,975 shares of common stock at the public offering price.
The closing of the offering is expected to occur April 1 subject to the satisfaction of closing conditions.
More articles on supply chain:
ASC supply chain tip of the day: Clean up inconsistencies
Are you a materials manager or managed by your materials?
SIS named No. 1 ASC EHR vendor for 4th year straight — 3 insights
